Skip to main content

Table 2 Summarization of clinical profiles of patients with anti-AMPAR encephalitis

From: Clinical characteristics and prognosis of anti-alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor encephalitis

Demographics Range Mean N missing (%)
Sex   2 M/7F 0
Age (years) 50–76 59 0
mRS (initial) 1–5 4 0
mRS (last follow-up) 0–6 5 2 (22)
Onset to diagnosis (weeks) 3–57 18 1 (11)
Clinical symptoms N positive N missing (%)
Acute onset 3 33% 0
Subacute onset 3 33% 0
Chronic onset 3 33% 0
Amnesia 8 89% 0
Psychosis 8 89% 0
Ataxia 2 22% 0
Fever 2 22% 0
Sleep disorders 2 22% 0
Dysautonomia 2 22% 0
Numbness 2 22% 0
Dysarthria 2 22% 0
Dysphagia 2 22% 0
Deafness 1 11% 0
Altered levels of consciousness 1 11% 0
Involuntary movement 1 11% 0
Seizures 0 0% 0
Laboratory and MRI findings N Positive N misssing (%)
Only Blood AMPAR Ab (+) 3 33% 0
Only CSF AMPAR Ab (+) 0 0% 0
Blood and CSF AMPAR Ab (+) 6 67% 0
Other Onco-neuronal Abs 2 33% 3 (33)
Increased CSF protein 5 63% 1 (11)
Increased CSF WBC 1 13% 1 (11)
MRI abnormal 6 75% 1 (11)
EEG abnormal 3 60% 4 (44)
Tumor identified 6 67% 0
  1. Abbreviations: Ab Antibody, CSF Cerebrospinal fluid, CT Computed tomography, EEG Electroencephalogram, MRI Magnetic resonance imaging, mRS Modified Rankin scale, N Number, WBC White blood cells